Wire
Aquestive Therapeutics Signs New $150 Million Debt Facility
Aquestive Therapeutics (AQST) signed a new $150 million debt facility with funds managed by Oaktree Capital Management to refinance its existing $45 million debt facility, the company said Tuesday.The remainder of the facility will be available in tranches based on certain milestones and will be used to support the planned launch of Anaphylm for severe allergic reactions, including anaphylaxis, if approved by the FDA, the company said.Price: $4.36, Change: $+0.02, Percent Change: +0.46%
$AQST
